Elisigen

Elisigen is a pre-clinical stage biotechnology company focused on the development of next-generation mRNA-based therapeutics and vaccines. Co-founded by Nobel Laureate Dr. Drew Weissman, the company leverages foundational discoveries in nucleoside-modified mRNA to create treatments with enhanced stability and reduced immunogenicity. Its platform aims to address a broad range of medical challenges, including infectious diseases, oncology, and protein replacement for genetic disorders. By integrating advanced delivery technologies with optimized RNA sequences, Elisigen is working to expand the therapeutic potential of mRNA beyond current applications. The company is headquartered in Philadelphia, benefiting from a close association with the region's premier academic research institutions.